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Background. Acute and chronic orofacial pain can significantly impact overall health and functioning. Associations between fear
of pain and the experience of orofacial pain are well-documented, and environmental, behavioral, and cognitive components of
fear of pain have been elucidated. Little is known, however, regarding the specific genes contributing to fear of pain. Methods. A
genome-wide association study (GWAS; 𝑁 = 990) was performed to identify plausible genes that may predispose individuals to
various levels of fear of pain.The total score and three subscales (fear of minor, severe, and medical/dental pain) of the Fear of Pain
Questionnaire-9 (FPQ-9) were modeled in a variance components modeling framework to test for genetic association with 8.5M
genetic variants across the genome, while adjusting for sex, age, education, and income. Results.Three genetic loci were significantly
associated with fear of minor pain (8q24.13, 8p21.2, and 6q26; 𝑝 < 5×10−8 for all) near the genes TMEM65,NEFM,NEFL,AGPAT4,
and PARK2. Other suggestive loci were found for the fear of pain total score and each of the FPQ-9 subscales.Conclusions. Multiple
genes were identified as possible candidates contributing to fear of pain.The findings may have implications for understanding and
treating chronic orofacial pain.
1. Introduction
The experience of orofacial pain is distressing, with burden
observed at individual and societal levels. For instance,
people experiencing orofacial pain are likely to miss work,
have impaired sleep, and have poorer quality of life [1–3].
At a societal level, orofacial pain is estimated to cost the
United States over $4 billion annually, a product of healthcare
expense, disability, and lost productivity [4]. Orofacial pain
can be experienced acutely, as in the case of toothache or
pain related to a dental procedure, and/or chronically, such
as in temporomandibular joint disorder (TMD) or trigeminal
neuralgia [5]. The experience of acute orofacial pain is uni-
versal, and an estimated one-quarter to one-third of people
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will suffer from chronic orofacial pain during their lifetime
[6, 7]. Thus, orofacial pain represents a relatively prevalent
problem and a particularly important one given its potential
to impact health and functioning. Tomost effectively address
the problem of orofacial pain, it is necessary to develop
a comprehensive model of its etiology, which requires a
nuanced understanding of a range of contributing factors.
It is well established that the experience of pain, including
orofacial pain, is impacted to a large degree by psychological
phenomena. In the case of acute orofacial pain, for example,
the presence of moderate-to-high levels of fear is known
to intensify the pain experience, with strong associations
observed between fear and pain threshold and tolerance [8–
10]. Likewise, depression, anxiety, and history of posttrau-
matic stress disorder are associated with more intense, func-
tionally limiting, and/or treatment-resistant chronic orofacial
pain [11–14]. Indeed, chronic pain conditions, including
chronic orofacial pain, are considered to have both physical
and psychological etiologies, with emotion and other psycho-
logical variables frequently contributing to maintenance of
the condition [14–16].
One psychological phenomenon that is particularly
important in the experience of pain is fear of pain, which
is defined as dread of or apprehension about nociception
associated with environmental experiences or bodily phe-
nomena that cause pain [17, 18]. At high levels, fear of pain
can be irrational and maladaptive, negatively influencing
behavior and contributing to the maintenance of chronic
pain symptomatology via a pain-avoidance cycle [17]. For
example, fear of chronic orofacial pain can develop when
an individual is apprehensive about the recurrence of acute
orofacial pain flares or certain mandibular movements (e.g.,
chewing of certain foods). Avoidance and emotional distress
can continue, however, even after the resolution of the
initial condition or trauma, producing or contributing to
the chronicity of orofacial pain [17]. Hypervigilance to pain-
related stimuli, borne out of fear of pain, can maintain pain
behaviors, especially avoidance [19].
General fear of pain and fear of dental pain, specifically,
are associated with greater intensity and duration of acute
dental pain [10], and, importantly, fear of pain has been linked
to the experience of chronic orofacial pain [9, 20]. In other
chronic pain conditions (e.g., low back pain and headache),
fear of pain has been associated with poor outcomes such as
pain intensity, reduction in physical activity and movement,
disability, avoidance, complaining, and maladaptive help-
seeking [21–25]. Given that fear of pain may in general be
particularly important in the development and maintenance
of chronic orofacial pain, research that seeks to more com-
prehensively characterize fear of pain is critical.
Though fear of pain has been well described and is
relatively well researched [14] (see Asmundson et al., 2004
[17], for a review), extant literature primarily addresses
environmental, behavioral, and cognitive determinants, with
very limited attention given to genetic ones. In the case of
anxiety and fear generally, anxiety disorders have been shown
to have a moderate-to-high degree of heritability, suggesting
that genetic variants influence an individual’s risk of devel-
oping an anxiety disorder [26–28]. Moreover, a number of
specific genes, associated pathways, and gene-environment
interactions have been implicated in the development of
pathological fear and/or anxiety disorders [29, 30]. Only one
previous study, completed by the present research group,
has addressed the heritability of fear of pain, with results
indicating that such fear is heritable (34%) and shares a
genetic basis, in part, with dental care-related fear, a distinct
but related phenomenon [31]. These results are consistent
with other studies showing that genetic variation contributes
to dental care-related fear [32–35].
Given that fear of pain is heritable to some degree, it
is likely that genetic variants are etiologically important.
Therefore, the first genome-wide association study (GWAS)
of fear of pain was performed to identify specific genes
potentially driving the heritability of fear of pain. In brief,
GWAS involves testing associations between genotype and
phenotype for millions of individual single-nucleotide poly-
morphisms (SNPs; i.e., genetic variants) across the genome
to identify the genetic loci related to the phenotype of
interest. This preliminary study was completed to provide
specific direction for future research that will advance the
understanding of fear of pain, which latermay offer targets for
intervention for patients experiencing orofacial pain acutely,
chronically, or both.
2. Methods
2.1. Sample. Participants were members of families taking
part in a large, household-based, cross-sectional study carried
out by the Center for Oral Health Research in Appalachia
(COHRA1; previously described by Polk and colleagues [36]).
The primary aim of the COHRA1 research program was to
investigate themultiple factors contributing to the oral health
disparities observed in northern Appalachia [36]. Over 800
families with children aged 1–17 years were recruited from
West Virginia and western Pennsylvania into the COHRA1
cohort. Participants had dental examinations and provided
extensive demographic, medical, and psychosocial data,
along with oral microbial samples and DNA for genetic
analysis. Participants provided data during one study visit
each, which was completed between 2003 and 2009. For
analyses presented here, only participants aged 11 years
and older were included, given that this was the COHRA1
protocol cut-off age for administration of the fear of pain
self-report assessment instrument. All participants provided
informed consent, and all study protocols were approved
by the Institutional Review Boards of the University of
Pittsburgh and West Virginia University.
2.2. Fear of Pain Questionnaire-9. The COHRA1 protocol
included the Fear of Pain Questionnaire-9 (FPQ-9), a self-
report psychological assessment of fear of pain, which tapped
the psychological phenotypes used in this GWAS. The FPQ-
9 is patterned after its validated parent scale, the Fear of
Pain Questionnaire-III (FPQ-III) [37], and comprises three
subscales—fear of severe pain, fear of minor pain, and fear
of medical/dental pain. Extensive psychometric data are
available for the FPQ-III [38, 39]. Each subscale consists of
three items that yield psychometrically reliable and validated
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scores [37]. Total score ranges 9–45, with higher scores
indicating greater levels of fear of pain.
The FPQ-9 was developed as a self-report measure of fear
of pain to be administered to adults and adolescents; given
the reading level of FPQ-9 items, and the nature of their
content, administration of the FPQ-9 to younger children
is not developmentally appropriate. Thus, in developing the
study protocol, and to ensure validity of data collected, a
cut-off of 11 years was set for administration (and parent
completionwas disallowed as the FPQ-9 is an assessment tool
designed for adult and adolescent self-report).
2.3. Genotyping, Quality Assurance, and Imputation. DNA
was extracted from blood or saliva samples (which result
in equivalent genotypes [40]) and genotyped for over 560K
SNPs using the Illumina Human610-Quad_v1_B BeadChip
[41] by the Center for Inherited Disease Research at Johns
Hopkins University. The source of DNA (i.e., blood versus
saliva) and the method of sample collection were a function
of time of enrollment in study and based on optimal DNA
extraction methods available at that time [36]; of COHRA1
participants, 43% provided blood samples. Regardless of
source of DNA, standard data cleaning procedures were
conducted for all genetic data, as previously described [42,
43]. In brief, samples were interrogated for genotype call rate,
batch effects, chromosomal aberrations, expected and cryptic
relatedness, genetic sex, evidence of sample contamination,
and genetic ancestry. SNPs were interrogated for call rate,
deviations from Hardy-Weinberg equilibrium, discordance
among technical duplicates, and Mendelian errors among
biologically related samples. Based on these analyses, quality
assurance filters were implemented to omit poorly geno-
typing samples and SNPs. Imputation of unobserved SNPs
was performed as implemented in IMPUTE2 [44, 45] (after
prephasing with SHAPEIT2 [46]), utilizing haplotypes from
Phase 3 of the 1000 Genomes Project as the reference sample.
Imputed dosages were filtered on per-SNP and per-genotype-
per-person levels and translated to high-confidence hard
calls. Imputation quality filters were applied at the SNP level
(i.e., INFO score> 0.5) and genotype per individual level (i.e.,
genotype probability > 90%). A minor allele frequency filter
of 0.01 was applied to both genotyped and imputed SNPs.
2.4. Statistical Analysis. Independent-samples t-tests were
conducted to confirm whether and to what degree sex differ-
ences exist in the self-report of fear of pain for this sample,
as such differences have been widely reported in the fear
literature [47]. Multiple linear regression analyses were con-
ducted to determine relations between FPQ-9 total/subscale
scores (dependent variables) and possible covariates (i.e., age,
education, income, and sex); FPQ-9 total and subscale score
distributions were amenable to these analyses. The threshold
for statistical significance of t-test and regression analyseswas
𝑝 = 0.05.
To simultaneously account for the biological relationships
among participants in the COHRA1 cohort as well as any
population structure (i.e., genetic variation in the cohort due
to ancestry), a variance components modeling framework
was utilized for testing the association of each SNP with
dental fear, while accounting for the covariates of age, sex,
education, and household income as well as genetic sharing.
The software EMMAX [48] was used to fit the mixed model.
To make the mixed model approach computationally feasible
on the genome-scale, the method implemented in EMMAX
estimates the variance parameters for the dataset once, rather
than separately for each SNP tested. This simplification
assumes that any individual SNP has a small effect on the
phenotype, which is a safe assumption based on the given
results.
GWAS scans were performed for four phenotypes: the
FPQ-9 total score and each of the three subscales (minor pain,
severe pain, and medical/dental pain). Given the multiple
testing burden and the strong linkage disequilibrium (LD;
correlation among physically proximal genetic variants due
to population history) among SNPs, we used the consensus
threshold in the field to declare genome-wide statistical
significance at 𝑝 < 5 × 10−8. In addition, we interpreted
“suggestive” associations in light of any corroborating evi-
dence of relevant biological functions from external data
sources. Suggestive associations were defined as one order
of magnitude less than genome-wide significance; thus, the
threshold for significance in these analyses was 𝑝 < 5 × 10−7.
The Manhattan and quantile-quantile plots used to visualize
the results were generated using the GWASTools package in
R (R Foundation for Statistical Computing, Vienna, Austria)
[49]. LocusZoom [50] was used to create regional association
plots.
3. Results
The total number of participants in the COHRA1 dataset
aged 11 years and older who completed the FPQ-9 totaled
1,687. Of these, 104 participants were excluded due to miss-
ing responses for ≥20% of the FPQ-9 instrument. Of the
remaining 1,583 participants, 60 individuals weremissing less
than 20% of the FPQ-9 responses, which were imputed using
mean imputation. Of the 1,583 participants with available
phenotype data, complete covariate and genetic data were
available for 990, with ages ranging 12–74 years. After clean-
ing and filtering, a total of 8,591,557 SNPs were available for
the GWAS.
Characteristics of the 990 participants included in this
study sample are shown in Table 1, with bivariate correlations
amongdemographic variables presented inTable 2.Themean
age was 32.2 years (SD = 11.0), and majority of participants
were female, which reflects the study design targeting house-
holds including parents of minor children. Nearly half of
the samples were from households with annual incomes less
than $15,000. The majority of the sample had a high-school
education or greater; approximately 14% had a college degree
or greater.
Results of the independent-samples t-tests indicated a
mean difference between males and females in general fear
of pain, fear of minor pain, fear of severe pain, and fear
of medical/dental pain. The mean for females consistently
was higher and that of males lower: for general fear of
pain, 𝑡(988) = −7.376 (𝑝 < 0.001); fear of minor pain,
𝑡(988) = −3.745 (𝑝 < 0.001); fear of severe pain, 𝑡(988) =
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Table 1: Demographic characteristics of study sample.
Mean/N Std. deviation/%






African American 159 10.0%
Hispanic 13 0.8%
Native American/Asian/other 23 1.4%
Missing 21 1.3%
Income
Less than $10,000 USD 251 25.5%
$10,000 to $14,999 202 20.4%
$15,000 to $24,999 182 18.4%
$25,000 to $34,999 115 11.6%
$35,000 to $49,999 130 13.1%
$50,000 to $74,999 52 5.3%
$75,000 to $99,999 37 3.7%
$100,000 to $149,999 11 1.1%
$150,000 to $199,999 2 0.2%
$200,000 or more 8 0.8%
Education
No high school diploma 264 26.7%
High school diploma/GED 371 37.5%
Technical school 115 11.6%
Some college, no degree 105 10.6%
Undergraduate degree 84 8.5%
Graduate degree 51 5.2%
Fear of pain
Total score 23.6 8.1
Fear of minor pain 6.0 2.5
Fear of severe pain 9.8 3.7
Fear of medical/dental pain 7.7 3.3
Table 2: Bivariate correlations of covariates used in GWAS model.
Sex Age Education Income
Sex 1
Age −.030 1
Education .078∗ .382∗∗ 1
Income −.007 −.011 .006 1
Note.𝑁 = 990. ∗ = correlation is significant at the 0.05 level (2-tailed); ∗∗ =
correlation is significant at the 0.01 level (2-tailed).
−7.239 (𝑝 < 0.001); and fear of medical/dental pain, 𝑡(988) =
−7.013 (𝑝 < 0.001). Multiple linear regression analyses
also were indicative of significant relations between sex, age,
education, and household income and fear of pain total
and subscale scores, justifying their inclusion in the GWAS
analyses as covariates. The results of the regression models
are included in Tables 3, 4, 5, and 6.
Figure 1 shows theManhattan and quantile-quantile plots
for GWAS scans of the FPQ-9 total score and minor, severe,
and medical/dental subscales. The genomic inflation factor
ranged from 0.998 to 1.014 across the four scans, indicating
no evidence of systematic bias in the behavior of the test
statistic. Three genetic loci met the threshold for genome-
wide significance (𝑝 < 5 × 10−8) for fear of minor pain.
These loci are depicted in the regional association plots shown
in Figure 2, and the details for the leading SNPs are shown
in Table 7. The most significant association was observed
between fear of minor pain and a region on chromosome
8q24.13 (leading SNP rs113248907; 𝑝 = 1.91 × 10−10) near
the gene TMEM65. The leading SNP is intergenic and not in
a known regulatory element. Other genome-wide significant
associations with fear of minor pain were observed for
regions on chromosomes 8p21.2 (leading SNP rs73547001;
intronic; 𝑝 = 1.30 × 10−8) in LOC105379330 (an unchar-
acterized locus that may be a pseudogene or noncoding
RNA) near the genes NEFM and NEFL and 6q26 (leading
SNP rs73782827; intronic; 𝑝 = 3.05 × 10−8) near the genes
AGPAT4 and PARK2. Of note, rs73547001 is in a LOC gene;
LOC105379330 is an uncharacterized locus that may be a
pseudogene or noncoding RNA.
In addition to the significant associations observed with
fear of minor pain, “suggestive” associations were observed
across the four GWAS scans. Details for the leading SNP in
these regions are shown in Table 7.
4. Discussion
Fear of pain is a complex psychological phenomenon that is
multifaceted and can contribute to the experience of acute
and chronic pain [17]. Fear of pain may be etiologically
important in cases of orofacial pain, given the role of
emotion in the development and maintenance of orofacial
pain problems [14]. In this study, genome-wide association
scans were carried out to identify genes that may be related
to fear of pain. The objective was to advance the literature
suggesting that genetic variation contributes to the etiology
of fear of pain by specifying which genes may be implicated.
Three genome-wide significant associations between
genetic loci and fear of minor pain were observed, and
numerous suggestive associations were observed between
genetic loci and general fear of pain (i.e., FPQ-9 total
score), fear of minor pain, fear of severe pain, and fear of
medical/dental pain (i.e., FPQ-9 subscale scores). Genes near
the genome-wide significant loci included TMEM65, NEFM,
NEFL, AGPAT4, and PARK2. Of these genes, TMEM65
(transmembrane protein 65) is the most interesting in the
context of fear of pain. TMEM65 is among the most dif-
ferentially methylated in people with chronic widespread
musculoskeletal pain [51] and also has been implicated in
abnormal pain threshold and predisposition to neuropathic
pain in rats [52]. Associations withNEFM andNEFL also are
interesting, as they are associated with neuronal functioning,
especially for motor neurons [53, 54] and may be distally
related to pain experience.
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Table 3: Multiple linear regression results for FPQ-9 total score.
Model B SE 𝛽 t p Lower bound Upper bound
1
(Constant) 19.717 .943 20.911 <0.001 17.866 21.567
Age .061 .025 .082 2.461 0.014 .012 .109
Education −.091 .187 −.016 −.488 0.626 −.458 .276
Income −.104 .131 −.025 −.798 0.425 −.361 .152
Sex 3.861 .517 .232 7.468 <0.001 2.846 4.875
Note. B = raw regression coefficient. SE = standard error. 𝛽 = standardized regression coefficient. Sex dichotomized as males = 0; females = 1.
Table 4: Multiple linear regression results for FPQ-9 fear of medical/dental pain subscale score.
Model B SE 𝛽 t p Lower bound Upper bound
1
(Constant) 6.789 .391 17.363 <0.001 6.002 7.557
Age .006 .010 .020 .592 0.554 −.014 .026
Education −.113 .078 −.049 −1.452 0.147 −.265 .040
Income −.015 .054 −.008 −.269 0.788 −.121 .092
Sex 1.525 .214 .222 7.114 <0.001 1.104 1.946
Note. B = raw regression coefficient. SE = standard error. 𝛽 = standardized regression coefficient. Sex dichotomized as males = 0; females = 1.
Table 5: Multiple linear regression results for FPQ-9 fear of severe pain subscale score.
Model B SE 𝛽 t p Lower bound Upper bound
1
(Constant) 8.010 .426 18.800 <0.001 7.174 8.846
Age .022 .011 .066 1.970 0.049 .000 .044
Education .172 .084 .068 2.035 0.042 .006 .338
Income −.054 .059 −.028 −.909 0.364 −.170 .062
Sex 1.665 .234 .221 7.126 <0.001 1.206 2.123
Note. B = raw regression coefficient. SE = standard error. 𝛽 = standardized regression coefficient. Sex dichotomized as males = 0; females = 1.
Table 6: Multiple linear regression results for FPQ-9 fear of minor pain subscale score.
Model B SE 𝛽 𝑡 𝑝 Lower bound Upper bound
1
(Constant) 4.917 .298 16.482 <0.001 4.332 5.502
Age .033 .008 .142 4.188 <0.001 .017 .048
Education −.151 .059 −.087 −2.544 0.011 −.267 −.034
Income −.036 .041 −.027 −.870 0.385 −.117 .045
Sex .671 .164 .129 4.102 <0.001 .350 .992
Note. B = raw regression coefficient. SE = standard error. 𝛽 = standardized regression coefficient. Sex dichotomized as males = 0; females = 1.
Perhaps most intriguing is the finding that fear of minor
pain was the only phenotype for which significant associa-
tions with genetic loci were observed at a genome-wide level.
Though suggestive associations were observed for general
fear of pain, fear of severe pain, and fear of medical/dental
pain, the associations observed for fear of minor pain showed
stronger statistical evidence. It may be the case that fear of
minor pain differentiates individuals who are particularly
pain fearful, with biological underpinnings. To be fearful of
severe pain and/or medical/dental pain is perhaps normative,
although individuals differ in those regards along a contin-
uum as well [37]. To be phenotypically different in fear of
minor pain, however, argues for substantive, perhaps even
qualitative individual differences. In the realm of orofacial
pain, fearing minor pain may influence “distress tolerance”
[55] of even minor dental procedures, seeking of analgesic
medications, and delay or avoidance of needed dental care. It
is plausible, for instance, that genetic predisposition impacts
certain biological pathways associated with sensitivity to low-
level pain or distress intolerance, making people more likely
to experience and find distressingminor pain, contributing to
fear of minor pain [56]. This finding may have implications
for understanding the etiological role of fear of pain in the
experience of chronic orofacial pain, as it can be characterized
by lower-level, annoying background pain.
In carrying out the GWAS to determine which genes may
be related to fear of pain, several demographic covariates
were controlled for after being analyzed by multiple linear
regression, and results from those regression analyses are
interesting in their own right. Consistent with previous
literature [57, 58], females tended to report higher levels of
pain-related fear (generally and across all FPQ-9 subscales)
and males lower levels. This trend is observed broadly across
fear literature, and researchers have suggested actual sex
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Figure 1:Manhattan plots (a) show the –log10-transformed𝑝 value (𝑦-axis), indicating significance of the association, for each SNP across the
genome (𝑥-axis; organized by physical position on each chromosome).The horizontal dashed lined indicates the threshold for genome-wide
significance. Quantile-quantile plots (b) show the –log10-transformed 𝑝 values observed in the GWAS (𝑦-axis) plotted against the expected
distribution of 𝑝 values under the null hypothesis of no association. Chromosome 23 is the X chromosome.
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Figure 2: Regional association plots for loci significantly associated with fear of minor pain. Each point depicts the significance (–log10-
transformed 𝑝 value; 𝑦-axis) and physical position (Mb; left 𝑥-axis) of a SNP. The leading SNP is shown as a purple circle and its reference
sequence designation is indicated. Open circles represent imputed SNPs, and closed circles represent genotyped SNPs. The coloring of the
points represents the LD (i.e., correlation; 𝑟2) of the SNP with the leading SNP. The blue recombination rate overlay (cM/Mb; right 𝑥-axis)
provides information about the LD-block structure of region. Locations of known genes are shown below the plot.
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Table 7: Results for the leading SNP for loci showing significant or suggestive evidence of association with fear of pain.
Phenotype SNP Chr. BP A1 A2 MAF Type Info Beta 𝑝
Total
rs73782827 6 161667052 G T 0.01 Imputed 0.91 −10.84 9.87𝐸 − 07
rs112510117 8 125429261 A G 0.01 Imputed 0.912 −8.44 7.16𝐸 − 07
rs7084783 10 105324170 G A 0.49 Imputed 0.982 −1.69 2.44𝐸 − 06
rs56875752 17 12599002 C A 0.11 Imputed 0.976 2.91 5.94𝐸 − 07
Minor
rs1146361 1 116658817 C T 0.15 Imputed 0.994 −0.81 8.12𝐸 − 07
rs6542838 2 99452458 C T 0.44 Imputed 0.997 −0.61 1.56𝐸 − 07
rs113865232 2 225213815 T C 0.01 Imputed 0.986 −2.63 6.74𝐸 − 07
rs13411339 2 237231135 T C 0.03 Imputed 0.961 −1.77 9.12𝐸 − 07
rs9871066 3 97202242 G A 0.02 Imputed 0.993 −2.56 3.44𝐸 − 07
rs2699039 4 160353222 A G 0.02 Imputed 0.993 −2.54 3.74𝐸 − 07
rs73746987 6 71820675 T C 0.01 Imputed 0.974 −3.40 2.26𝐸 − 07
rs73782827 6 161667052 G T 0.01 Imputed 0.91 −3.80 3.05𝐸 − 08
rs34139189 6 162293644 G A 0.14 Imputed 0.796 −0.93 8.22𝐸 − 07
rs73547001 8 24862630 G A 0.01 Imputed 0.89 −3.35 1.30𝐸 − 08
rs73700552 8 107068214 C T 0.01 Imputed 0.969 −3.43 1.30𝐸 − 07
rs113248907 8 125418123 A C 0.01 Imputed 0.95 −3.41 1.91𝐸 − 10
rs1871535 8 145639586 C T 0.02 Imputed 0.878 −2.09 2.91𝐸 − 07
rs12252682 10 93810742 C G 0.02 Imputed 0.852 −2.45 5.89𝐸 − 07
rs687735 11 64047152 A G 0.01 Imputed 0.874 −3.26 8.96𝐸 − 07
rs11871659 17 40692638 C T 0.03 Imputed 0.979 −2.08 5.27𝐸 − 07
rs2223785 20 30676316 C T 0.02 Imputed 0.968 −2.80 3.39𝐸 − 07
rs6008192 22 47804243 T G 0.01 Imputed 0.931 −2.99 4.79𝐸 − 07
rs73558352 23 123751759 T G 0.02 Imputed 0.639 −2.00 4.84𝐸 − 07
Severe
rs553086 11 56852098 A G 0.23 Genotyped 1 0.92 2.69𝐸 − 06
rs10844026 12 31994740 A T 0.24 Imputed 0.995 −0.95 7.69𝐸 − 07
rs61923480 12 54884202 C A 0.02 Imputed 0.915 2.52 4.28𝐸 − 07
rs61930374 12 71271433 C G 0.20 Imputed 0.933 −1.09 5.12𝐸 − 07
rs112664965 13 51050827 A G 0.04 Imputed 0.997 −1.88 2.18𝐸 − 06
rs7178691 15 53899306 A G 0.32 Imputed 1 −0.82 2.86𝐸 − 06
rs56875752 17 12599002 C A 0.11 Imputed 0.976 1.38 1.57𝐸 − 07
rs3975333 19 53805815 T A 0.09 Imputed 0.793 1.49 2.29𝐸 − 06
Medical
rs114134414 1 74708559 C A 0.03 Imputed 0.899 2.15 9.29𝐸 − 07
chr2:99411513 2 99411513 A T 0.14 Imputed 0.719 −1.29 1.43𝐸 − 06
rs72965720 6 128023381 C A 0.08 Imputed 0.999 1.43 2.06𝐸 − 07
rs9901616 17 29336745 T C 0.03 Imputed 0.895 −2.31 7.69𝐸 − 07
rs10422046 19 982968 A G 0.11 Imputed 0.761 1.38 1.22𝐸 − 06
rs5979239 23 10009993 A G 0.04 Imputed 0.972 −2.04 1.82𝐸 − 06
Note. chr. = chromosome; BP = base position; A1 = minor (effect) allele; A2 = major allele; MAF = minor allele frequency; info = imputation information
metric, an indicator imputation quality; beta = effect size per minor allele.
differences in the experience of many fears/anxieties, report-
ing biases driven by social norms and/or gender differences in
communication style as potentially contributing to the noted
difference [47]. In the case of fear of pain, specifically, sex
differences in pain perception also may play a role [59, 60].
For general fear of pain, fear of severe pain, and fear of
minor pain, age was a significant predictor. Contemporary
literature on the effects of age on pain-related fear is mixed
and somewhat inconclusive [61]; however, the findings of
the current study generally are consistent with previous
work suggesting that as an individual’s age increases, levels
of pain-related fear decrease [62]. It may be that, with
age and life experience, people are desensitized to pain-
related stimuli such that a reduction in fear is observed [63].
Likewise, for fear of severe pain and fear of minor pain,
education was a significant predictor, with greater education
associated with lower fear of pain. This finding is consistent
with literature demonstrating an association between lower
level of education and fear-avoidance beliefs about physical
activity in pain patients [64], and it may be that, generally,
education can protect people from developing maladaptive
or irrational fears [65]. Additional research is needed to fully
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understand how covariates such as sex, age, and education
influence fear of pain.
Some study limitations are noted. First, the study, by
design, is cross-sectional in nature with correlational results.
Causality cannot be inferred from study results and follow-
up studies are necessary to elucidatemechanisms of observed
associations. Second, fear of pain data are self-reported.
While the instrument used to assess fear of pain is a valid
and reliable one, measurement of complex psychological or
behavioral phenotypes is stronger when multimodal assess-
ment methods are utilized (e.g., combined use of objective
behavioral observation, cognitive assessment or neuroimag-
ing, clinician-rated measures, and/or physiological assess-
ment) [66]. Third, the study sample was recruited from one
region of the United States and is relatively homogenous with
regard to ethnicity and cultural background, which may bias
the experience or reporting of phenotypes like fear of pain,
potentially limiting the generalizability of the study. Similar
analyses should be completed with other and/ormore diverse
samples. Lastly, the sample utilized for this study was modest
in size for a GWAS, and it is acknowledged that many true
associations may have gone undetected due to low power to
detect variants of small effect and/or low frequency.
Considering the design of this study, GWAS is under-
stood to be a discovery-driven approach aimed at creating
hypotheses. Thus, study results are considered to be prelimi-
nary and should guide future research in the area. Replication
of the study with other samples is necessary. Moreover,
future research should seek to confirm the findings presented
here through the use of epidemiological or experimental
approaches. Functional studies are needed to determine how
genetic loci observed to be associated with fear of pain are
related to the phenotype. Specific genes suggested by this
study to be related to fear of pain should be the subject of
future follow-up studies, potentially with attention paid to
possible mechanistic pathways that involve pain perception
(e.g., hypersensitivity to pain stimuli), anxiety/fear, anxiety
sensitivity, and/or distress tolerance. Also, the potentially
unique and important role of fear of minor pain in driving
general fear of pain and associated pain behaviors and
outcomes should be researched more comprehensively. Of
note, a recent meta-analysis of GWAS addressing anxiety
disorders revealed two genetic loci, rs1709393 and rs1067327,
significantly associatedwith anxiety and/or anxiety disorders,
across all published studies [67]. The current dataset was
analyzed for associations between variation at these loci and
fear of pain, with no evidence found. Future studies should
continue to address genetic contributions to anxiety, gener-
ally, with attention paid to genetic variation that accounts for
both general anxiety and fear of pain, specifically.
This study is one of only a few to address genetic
contributions to fear of pain, and it is the first to ana-
lyze genome-wide associations to offer avenues for future
research. Understanding the role of genetic variation in fear
of pain has the potential to improve our understanding
of the way emotions affect and are affected by the pain
experience. More immediately, discovering specific genetic
associationswith fear of pain advances amore comprehensive
understanding of this complex psychological phenomenon.
Given that fear of pain impacts acute orofacial pain and is
critically important in its development and maintenance and
is a major component of dental care-related anxiety and fear
[68], a more completely defined etiology of fear of pain could
ultimately refine the management and treatment of orofacial
pain by highlighting the best targets for intervention.
5. Conclusions
This study aimed to advance the understanding of genetic
contributions to fear of pain and was the first GWAS for
this psychological phenotype. In carrying out the study,
multiple demographic risk factors for higher fear of pain
were identified: being female is associated with increased
risk of general fear of pain and its components (i.e., fear
of medical/dental pain, fear of severe pain, and fear of
minor pain); younger age is associated with increased risk
of general fear of pain as well as fears of severe and minor
pain; and, having less education is associated with increased
risk of fears of severe and minor pain. There were three
genetic loci identified for fear of minor pain, which may
have implications for individuals with lower pain tolerance
or with chronic orofacial pain. Findings of this study should
guide follow-up genetic studies, including confirmatory ones
as well as epidemiological and experimental (e.g., functional
or mechanistic) investigations. Understanding genetic and
other contributions (such as demographic risk factors) to
fear of pain and the specific genes and variants influencing
individual differences in fear of pain could lead to innovative
ways of managing and mitigating orofacial and other pain,
particularly among those who suffer from chronic pain.
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